Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
TERMINATED
NA
28 participants
INTERVENTIONAL
2004-08-31
2015-07-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Efficacy of Topical Rapamycin to Treat Chronic Erosive Oral Lichen
NCT01061853
Efficacy of Topical Treatment With Clobetasol in Symptomatic Oral Lichen Planus.
NCT04364555
Comparison of Triamcinolone Acetonide Mucoadhesive Film and Licorice Mucoadhesive Film Effect on Lichen Planus
NCT02453503
Clinical and Immunohistochemical Effect of Topical Pimecrolimus in Treatment of Oral Lichen Planus
NCT02443311
Evaluation of the Efficacy of 0.08% Tacrolimus Nanoencapsulated Aqueous Solution Spray Vs. 0.1% Free Tacrolimus Commercial Ointment in the Treatment of Oral Lichen Planus
NCT06591884
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Tacrolimus
Tacrolimus ointment 0.1%, three times a day for 6-9 weeks.
0.1 % tacrolimus ointment
applied topically to oral mucosa
Triamcinolone
Triamcinolone paste 0.1%, three times a day for 3-6 weeks.
0.1 % triamcinolone paste
applied topically to oral mucosa
Placebo
Orabase paste, three times a day for 3-6 weeks.
Orabase paste
applied topically to oral mucosa
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
0.1 % tacrolimus ointment
applied topically to oral mucosa
0.1 % triamcinolone paste
applied topically to oral mucosa
Orabase paste
applied topically to oral mucosa
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Clinical score for OLP ≥ 20 at baseline
* Symptomatic OLP at baseline
* Washout period of 2 weeks
* Age over 18
Exclusion Criteria
* Allergy to tacrolimus or other macrolides
* Allergy to other drugs or substances used in the study
* Abnormal liver function
* Netherton's syndrome
* Cyclosporin medication
* Other regular medication that could have significant interactions with tacrolimus
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Kuopio University Hospital
OTHER
University of Oulu
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Tuula Salo, DDS, PhD
Role: PRINCIPAL_INVESTIGATOR
Department of Diagnostics and Oral Medicine, Institute of Dentistry, University of Oulu, Oulu, Finland
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Oral and Maxillofacial Diseases Clinic, Kuopio University Hospital
Kuopio, , Finland
Department of Diagnostics and Oral Medicine, Institute of Dentistry, University of Oulu
Oulu, , Finland
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
Takrolimuusi123
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.